{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rilzabrutinib", "query": { "intervention": "rilzabrutinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rilzabrutinib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-19T08:55:10.431Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04520451", "title": "Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunoglobulin G4 Related Disease" ], "interventions": [ { "name": "rilzabrutinib", "type": "DRUG" }, { "name": "Glucocorticoids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-08-22", "completion_date": "2024-10-15", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 5, "location_summary": "Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04520451" }, { "nct_id": "NCT03762265", "title": "A Study of PRN1008 in Patients With Pemphigus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pemphigus" ], "interventions": [ { "name": "Rilzabrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 131, "start_date": "2019-01-08", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-08-02", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 14, "location_summary": "Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03762265" }, { "nct_id": "NCT06444204", "title": "A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Function Abnormal", "Healthy Volunteers" ], "interventions": [ { "name": "Rilzabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2020-11-02", "completion_date": "2021-03-23", "has_results": false, "last_update_posted_date": "2024-06-05", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 2, "location_summary": "Miami, Florida • Orlando, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06444204" }, { "nct_id": "NCT05002777", "title": "Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Warm Autoimmune Hemolytic Anemia (wAIHA)" ], "interventions": [ { "name": "rilzabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2021-12-07", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 11, "location_summary": "Cerritos, California • Glendale, California • Long Beach, California + 7 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05002777" }, { "nct_id": "NCT04562766", "title": "Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immune Thrombocytopenia" ], "interventions": [ { "name": "Rilzabrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 232, "start_date": "2020-12-14", "completion_date": "2026-08-26", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Torrance, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04562766" }, { "nct_id": "NCT07086976", "title": "A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Autoimmune Haemolytic Anaemia" ], "interventions": [ { "name": "rilzabrutinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-08-18", "completion_date": "2029-12-26", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07086976" }, { "nct_id": "NCT07190196", "title": "A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immunoglobulin G4 Related Disease" ], "interventions": [ { "name": "Rilzabrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Glucocorticoid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2025-09-26", "completion_date": "2030-12-25", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 17, "location_summary": "Fontana, California • San Jose, California • Tustin, California + 14 more", "locations": [ { "city": "Fontana", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Margate", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190196" }, { "nct_id": "NCT06500702", "title": "A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Segmental Glomerulosclerosis", "Glomerulonephritis Minimal Lesion" ], "interventions": [ { "name": "frexalimab", "type": "DRUG" }, { "name": "brivekimig", "type": "DRUG" }, { "name": "rilzabrutinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 84, "start_date": "2024-12-19", "completion_date": "2028-02-16", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06500702" }, { "nct_id": "NCT06975865", "title": "The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Rilzabrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "10 Years to 65 Years" }, "enrollment_count": 192, "start_date": "2025-08-12", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06975865" }, { "nct_id": "NCT06444191", "title": "Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Rilzabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 23, "start_date": "2021-01-04", "completion_date": "2021-04-12", "has_results": false, "last_update_posted_date": "2024-06-05", "last_synced_at": "2026-09-19T08:55:10.431Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06444191" } ] }